Some recommendations for patients of rheumatic diseases

In such co-operation of this kind, an expert panel of rheumatologists and orthopedic surgeons has drafted instructions for perioperative management of anti-reumatic drugs in patients subject to total hip or knee replacement.

” Patients with rheumatic diseases that have the intervention of replacing hips are at high risk for common infection, a potentially devastating complications.”, said Susan Goodman, MD, a key co-investigator and a rheumatologist at New York City's Special Surgery Hospital.

Since the risk of infection is linked to the use of anti-reumatic drugs, the goal was to develop recommendations on when to stop medicines before replacing the basin and optimum time for patients to resume post-operation treatment.

The proper management of drugs in the perioperative period can provide an important opportunity to reduce the risk of infection or other adverse results. ”

The American College of Reumatology (ACR) and the American Association of Legen/Hurperation sponsored the project and instructions were published in Artritie Care & Research, a revised medical magazine of ACR and the Association of Reumatological Health Professionals. The recommendations are based on a broad review of available literature on this subject, clinical expertise and experience, and the contribution of patients.

The study included traditional anti-reumatic drugs ( DMARDs), biological agents, tophacitineb and glucose. The panel has drafted instructions on when it needs to continue, when it needs to sustain and when it needs to resume these drugs, as well as the opiperative dose of cortichosteroids, writes Shneta.